ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate. These key neurotransmitters – known to regulate mood, behaviour, and bodily functions – have served as the ...

Omeros Corporation (NASDAQ:OMER) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. Latest reports show that Omeros Corporation (NASDAQ:OMER) has closed a deal worth around $2.1 ...

New psychoactive substances (NPS) are a class of artificially designed and synthesized chemical substances designed to mimic the pharmacological effects of traditional drugs. They are characterized by ...

Psychedelic stocks focus on hallucinogenic treatments, carrying significant growth potential but high volatility. Recent clinical trials show promise in treating depression and anxiety, boosting ...